Dynavax Technologies (NASDAQ:DVAX) Price Target Cut to $15.00

Dynavax Technologies (NASDAQ:DVAX) had its price objective decreased by The Goldman Sachs Group from $20.00 to $15.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 35.14% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Wednesday. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies currently has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Stock Up 3.7 %

DVAX stock traded up $0.40 during trading on Thursday, reaching $11.10. 2,976,587 shares of the company traded hands, compared to its average volume of 2,151,702. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 185.00 and a beta of 1.28. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. The business has a 50 day simple moving average of $11.20 and a 200 day simple moving average of $11.84. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million for the quarter, compared to analysts’ expectations of $76.92 million. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. During the same period last year, the business earned $0.03 EPS. On average, equities research analysts anticipate that Dynavax Technologies will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Francis Cano sold 3,615 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.93, for a total value of $43,126.95. Following the completion of the transaction, the director now owns 36,905 shares in the company, valued at approximately $440,276.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dynavax Technologies

A number of large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Dynavax Technologies by 7.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,116 shares of the biopharmaceutical company’s stock valued at $1,218,000 after purchasing an additional 6,296 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Dynavax Technologies by 185.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 118,074 shares of the biopharmaceutical company’s stock valued at $1,651,000 after buying an additional 76,728 shares during the period. Executive Wealth Management LLC purchased a new stake in shares of Dynavax Technologies in the fourth quarter worth about $280,000. Louisiana State Employees Retirement System acquired a new stake in Dynavax Technologies during the fourth quarter worth about $905,000. Finally, Handelsbanken Fonder AB grew its holdings in Dynavax Technologies by 3.4% during the fourth quarter. Handelsbanken Fonder AB now owns 27,300 shares of the biopharmaceutical company’s stock worth $382,000 after acquiring an additional 900 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.